QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.059477v1 309/1/64    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Han, Y. Articles by Pan, S.-s. Search for Related Content PubMed PubMed Citation Articles by Han, Y. Articles by Pan, S.-s.

CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

NAD(P)H:Quinone Oxidoreductase-1-Dependent and -Independent Cytotoxicity of Potent Quinone Cdc25 Phosphatase Inhibitors

Departments of Pharmacology (Y.H., J.S.L., S.P.), Radiation Oncology (H.S.), Surgery (B.I.C.), and Chemistry (P.W.), University of Pittsburgh, Pittsburgh, Pennsylvania

Cdc25 dual-specificity phosphatases coordinate cell cycle progression and cellular signaling. Consequently, Cdc25 inhibitors represent potential anticancer agents. We evaluated >10,000 compounds for inhibition of human Cdc25 phosphatases and identified many potent and selective inhibitors, which all contained a quinone. Bioreductive enzymes frequently detoxify or activate quinones. Therefore, we evaluated the effect of NAD(P)H:quinone oxidoreductase-1 (NQO1) and reductase-rich microsomes on the activity of three quinone-containing Cdc25 inhibitors: 2-(2-hydroxyethylsulfanyl)-3-methyl-1,4-naphthoquinone (Cpd 5, compound 5; NSC 672121), 2,3-bis-(2-hydroxyethylsulfanyl)-1,4-naphthoquinone (NSC 95397), and 6-chloro-7-(2-morpholin-4-yl-ethylamino)quinoline-5,8-dione (NSC 663284). Each inhibitor was reduced by human NQO1 (K_m of 0.3–0.5 µM) but none by microsomes. Compounds were evaluated with six cancer cell lines containing different amounts of NQO1: HT-29 (1056 nmol/mg/min), HCT116 (660 nmol/mg/min), sublines HCT116-R30A (28 nmol/mg/min) and HCT-116R30A/NQ5 (934 nmol/mg/min), MDA-MB-231/Q2 (null NQO1), and subline MDA-MB-231/Q6 (124 nmol/mg/min) but containing similar amounts of microsomal cytochrome P450 reductase and cytochrome b₅ reductase. Growth inhibition and G2/M arrest by Cpd 5 was proportional to NQO1 levels, requiring 4- to 5-fold more Cpd 5 to inhibit HCT-116 or HCT-116R30A/NQ5 compared with HCT-116R30A. In contrast, in all tested cell lines irrespective of NQO1 level, growth inhibition and G2/M arrest by NSC 95375 and NSC 663284 were similar (average IC₅₀ of 1.3 ± 0.3 and 2.6 ± 0.4 µM, respectively). NSC 95375 and NSC 663284 also caused similar Cdk1 hyperphosphorylation, indicating similar Cdc25 inhibition. However, lower Cpd 5 concentrations were needed to produce Cdk1 hyperphosphorylation in sublines with minimal NQO1. Thus, NQO1 detoxified Cpd 5, probably by reducing it to a less active hydroquinone, whereas NSC 95397- and NSC 663284-generated cytotoxicity was unaffected by NQO1.

Address correspondence to: Dr. Su-shu Pan, University of Pittsburgh Cancer Institute, Rm G27, Hillman Cancer Center, 5117 Centre Ave., Pittsburgh, PA 15213. E-mail: pans{at}msx.upmc.edu

This article has been cited by other articles:

				M. Volpato, N. Abou-Zeid, R. W. Tanner, L. T. Glassbrook, J. Taylor, I. Stratford, P. M. Loadman, M. Jaffar, and R. M. Phillips Chemical synthesis and biological evaluation of a NAD(P)H:quinone oxidoreductase-1 targeted tripartite quinone drug delivery system Mol. Cancer Ther., December 1, 2007; 6(12): 3122 - 3130. [Abstract] [Full Text] [PDF]

				S. Kar, M. Wang, W. Yao, C. J. Michejda, and B. I. Carr PM-20, a novel inhibitor of Cdc25A, induces extracellular signal-regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol. Cancer Ther., June 1, 2006; 5(6): 1511 - 1519. [Abstract] [Full Text] [PDF]

				M. Brisson, T. Nguyen, P. Wipf, B. Joo, B. W. Day, J. S. Skoko, E. M. Schreiber, C. Foster, P. Bansal, and J. S. Lazo Redox Regulation of Cdc25B by Cell-Active Quinolinediones Mol. Pharmacol., December 1, 2005; 68(6): 1810 - 1820. [Abstract] [Full Text] [PDF]